Trial Profile
A phase I study investigating the combination of everolimus with pemetrexed in patients with advanced non small cell lung cancer (NSCLC) previously treated with chemotherapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Dec 2012
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Novartis
- 18 May 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 18 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Nov 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.